FSD Pharma Inc (CSE:HUGE) (“FSD Pharma” or the “Company”) is pleased to announce that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”).
FSD Pharma Inc (CSE:HUGE) (“FSD Pharma” or the “Company”) is pleased to announce that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”). Local politicians and media will be in attendance at the ribbon-cutting ceremony on October 9, 2018 at 11:30 EST in Cobourg at the Head office located at 520 William Street. Honoured invited guests include Cobourg Mayor Gil Brocanierwho will be in attendance and the Hon. Kim Rudd, MP for Northumberland and Peterborough South who is expected to attend. All national media are welcome with media credentials.
Thomas Fairfull, President and CEO of FSD Pharma stated, “We welcome politicians and media to this momentous event where we begin converting the historic Certo building located at the former Kraft plant into a heritage museum and on-site dispensary. The Certo building is an important part of Cobourg’s history and the Company intends to preserve this unique building.”
The former Certo building was the first in the British Empire to make commercial grade pectin that was sold under the product name of “Certo” and is estimated at over 100 years old. The property is listed on the municipal heritage register as a property of cultural heritage value. Last year, Cobourg City Council endorsed several recommendations, including the designation of the Certo building under the Ontario Heritage Act as a building of cultural heritage value.
“Today, we also begin construction of our flagship on-site dispensary, an important component of our business plan as we sit on the brink of adult-use legalization on October 17, 2018. The Company is preparing in earnest for sales of our high quality, indoor grown and pharmaceutical grade product, which will be available for sale shortly,” continued Fairfull.
About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)
FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
For further information: Thomas Fairfull, President and CEO, Email: email@example.com, Telephone: (905) 686-7079; Investor Relations, Email: IR@fsdpharma.com, Website: www.fsdpharma.com